LXEO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LXEO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Lexeo Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $0. Lexeo Therapeutics's 10-Year median PS Ratio is . Therefore, the Median PS Value for today is $0.00.
As of today (2024-06-09), Lexeo Therapeutics's share price is $17.25. Lexeo Therapeutics's Median PS Value is $0.00. Therefore, Lexeo Therapeutics's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for Lexeo Therapeutics's Median PS Value or its related term are showing as below:
The historical data trend for Lexeo Therapeutics's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexeo Therapeutics Annual Data | |||||||||
Trend | Dec20 | Dec21 | Dec22 | Dec23 | |||||
Median PS Value | - | - | - | - |
Lexeo Therapeutics Quarterly Data | ||||||||||
Dec20 | Dec21 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Median PS Value | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Lexeo Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Lexeo Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Lexeo Therapeutics's Price-to-Median-PS-Value falls into.
Lexeo Therapeutics's Median PS Value for today is calculated as
Median PS Value | = | Revenue per Share (TTM) | * | 10-Year Median PS Ratio |
= | 0 | * | ||
= | 0.00 |
10-Year Median PS Ratio is .
Lexeo Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexeo Therapeutics (NAS:LXEO) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Lexeo Therapeutics's Price to Median PS Value for today is calculated as
Price to Median PS Value | = | Share Price | / | Median PS Value |
= | 17.25 | / | 0.00 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Lexeo Therapeutics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Lundbeckfond Invest A/s | 10 percent owner | SCHERFIGSVEJ 7, COPENHAGEN G7 DK-2100 |
Longitude Capital Partners Iv, Llc | 10 percent owner | 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025 |
Omega Fund Vi Gp, L.p. | 10 percent owner | 888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199 |
Omega Fund Vi, L.p. | 10 percent owner | 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199 |
Richard Nolan Townsend | director, officer: Chief Executive Officer | C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010 |
Jenny Robertson | officer: Chief Legal and Admin. Officer | C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010 |
Paul Mccormac | officer: Chief Technical Officer | C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010 |
Bernard Davitian | director | C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010 |
Eric Adler | officer: Chief Scientific Officer | C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK NY 10010 |
Brenda Cooperstone | director | C/O SENTI BIOSCIENCES, INC., 2 CORPORATE DRIVE FIRST FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Longitude Venture Partners Iv, L.p. | 10 percent owner | 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025 |
Omega Fund Vi Gp Manager, Ltd. | 10 percent owner | 888 BOYLSTON STREET, SUITE 1111, BOSTON MA 02199 |
Paula H Cholmondeley | director | 221 W PHILADELPHIA ST, SUITE 60W, YORK PA 17401-2991 |
Reinaldo M Diaz | director | C/O DIAZ & ALTSCHUL CAPITAL, 950 THIRD AVE, NEW YORK NY 10022 |
Mette Kirstine Agger | director | C/O SCPHARMACEUTICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01830 |
From GuruFocus
By GuruFocus Research • 12-13-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.